News

The director of the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the use of MSC-NTF cells in progressive MS and the data backing this approach. [WATCH TIME: 3 minutes]

The registered dietitian at Ann & Robert H. Lurie Children’s Hospital of Chicago provided knowledge on the how and why diets are constructed for patients with epilepsy.

Investigators highlighted the need to integrate research frameworks to analyze and understand these interrelationships, developing appropriate interventions for the Black, Latinx, and Hispanic populations with NMOSD and MS.

The research chair for Parkinson’s Disease and Movement Disorders at University of Cincinnati Health discussed the therapy’s results in a study of its effect on Parkinson disease. [WATCH TIME: 6 minutes]

Discussing the 3 FDA-approved treatments for NMOSD, the clinical research director of the UCSF Multiple Sclerosis Center commented on the positive impact, as well as resultant barriers to care. [WATCH TIME: 4 minutes]

In the cohort of 14 patients with preoperative impulsive and compulsive behavior burden, 6 patients demonstrated clinically relevant improvement on QUIP-RS, while 1 worsened and 7 remained stable.

The neurologist at Wayne State University provided background on why there needs to be a continued focus on including and studying African American patients with NMOSD in trials. [WATCH TIME 3 minutes]

Investigators observed a significant difference in the hazard ratio change on NPI apathy score within the first 100 days, suggesting an early treatment effect.

A large-scale rural population study included approximately 27,935 men and women, finding that sleep quality might predict risk of coronary heart disease.

The clinical research director of the UCSF Multiple Sclerosis Center provided an overview on the state of care for NMOSD, specifically the development of inebilizumab, satralizumab, and eculizumab. [WATCH TIME: 6 minutes]

The pivotal phase 3 GRADUATE 1 and 2 trials will evaluate the effect of gantenerumab on amyloid load and downstream biomarkers of disease progression in patients with early Alzheimer disease.

Gennero Pagano, MD, MSc, PhD, expert medical director, Roche, provided thoughts on the investigational agent prasinezumab, overall Parkinson drug development, and MDS Virtual Congress.

The registered dietitian at Ann & Robert H. Lurie Children’s Hospital discussed the unknowns in terms of managing and prescribing diets for patients with epilepsy. [WATCH TIME 3 minutes]

Here's what is coming soon to NeurologyLive.

Investigators used the Baveno classification to group patients at diagnosis of obstructive sleep apnea and again after 5 years.

Some of the most frequently reported trial criteria were the exclusion of participants with non-AD neurological disease, psychiatric illness, cardiovascular and cerebrovascular disease, obligated caregiver attendance, and cognitive impairment.

The division chief of vascular neurology at the University of Utah discussed the individual role that clinicians and neurologists can play to increase interest in the field of neurology. [WATCH TIME: 2 minutes]

Patients who were dementia-free with the lowest PF had smaller volumes of total brain, gray matter, and white matter, and had greater white matter hyperintensities.

Clinical data on the investigational therapeutics, DNL343 and SAR443820/DNL788, were presented at the 2021 Annual Northeast ALS Meeting this month.

Neurology News Network for the week ending October 9, 2021. [WATCH TIME: 3 minutes]

Preclinical results showed promise for the investigational formulation in reducing seizures, prompting the patent filing.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 8, 2021.

Following the publication of a recent article outlining the association of the use of anesthesia during surgery and cognitive decline in older adults, the assistant professor of anesthesiology at the David Geffen School of Medicine, UCLA, spoke on the need to assess risk factors. [WATCH TIME: 5 minutes]

Patients treated in the 10- and 20-mg once daily groups showed statistically significant improvements in UPDRS parts II, III, IV, and in total MDS-UPDRS scores compared with baseline.

The registered dietician at Ann & Robert H. Lurie Children’s Hospital of Chicago provided insight on the importance of educating youths with epilepsy on diets, especially in the transition stages of care. [WATCH TIME: 2 minutes]

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Gregory W. Albers, MD.

The organization called attention to unintended harms of the current Medicare benefit structure and the need for the Center for Medicare & Medicaid Services to be more “patient-focused” in its assessments.

Investigators suggest recognition of predictors can aid in directing future clinical trials, as well as inform early therapeutic decisions in this patient population.

The assistant professor of anesthesiology at the David Geffen School of Medicine, University of California–Los Angeles, discussed a recently published article that outlined an association between anesthesia during surgery and cognitive issues. [WATCH TIME: 4 minutes]

Evanthia Bernitsas, MD, neurologist, Wayne State University, discussed a recently conducted analysis, which confirmed inebilizumab’s ability to treat African Americans with NMOSD.